Citigroup Inc Supernus Pharmaceuticals, Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 81,011 shares of SUPN stock, worth $2.72 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
81,011
Previous 77,439
4.61%
Holding current value
$2.72 Million
Previous $2.41 Million
21.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$348 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$206 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$162 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$96.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$88.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.79B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...